top of page

Bionote USA’s New Symmetric Dimethylarginine (SDMA) Test is Reliable, In-Clinic Indicator of Kidney Disease

Latest Test in Company’s Vcheck Line Provides Early Indication of Renal Diseases


BIG LAKE, MINN. (December 19, 2023) — Bionote USA, manufacturer of quantitative, point-of-care veterinary analyzers and biomarker tests, has released a new canine and feline Symmetric Dimethylarginine (SDMA) test in its Vcheck F line that provides quantitative levels of this biomarker to veterinarians at the point of care. Unlike some SDMA offerings that are only included on a larger panel with other tests, the Vcheck SDMA test is an independent biomarker test.


Relying on Bionote’s innovative and unique methodology, this new test has proven to be a more reliable marker of renal disease than the traditional creatinine and blood urea nitrogen (BUN) biomarkers. This is due to the earlier increase of SDMA than other markers in dogs and cats with both acute kidney injury and chronic kidney disease. Some sources indicate that renal disease has been found in nearly 7 percent of dogs and 20 percent of cats.1,2


SDMA is also not influenced by lean body mass, which can have an impact on creatinine levels. After results are established with an SDMA test, creatinine levels should still be measured as a complement, along with a review of patient history, physical examination and other testing to fully evaluate kidney function.


“The opportunity for earlier detection and treatment provided by this new test can help veterinarians alleviate symptoms and, in some cases, prevent kidney disease from progressing to the chronic stage,” said Randy Knick, president of Bionote USA.




Bionote’s new test provides in-clinic diagnostic, monitoring, staging and screening capabilities for veterinarians working with both dogs and cats. After a 100 µl sample of plasma or serum runs five minutes in a micro-centrifuge at 10,000 RPM, the test can be interpreted by the Vcheck F analyzer in just 11 minutes. A quantitative measurement ranging from 10.0 to 100.0 µg/dL is provided and rapidly indicates any necessary additional testing or intervention.


To learn more about Bionote USA and the Vcheck line of analyzers and 17 quantitative, in-clinic tests, or to place an order, contact Bionote sales through the company website


1. Lund, E. M., Armstrong, P. J., Kirk, C. A., Kolar, L. M. and Klausner, J. S. 1999. Health status and population characteristics of dogs and cats examined at private veterinary practices in the

United States. J. Am. Vet. Med. Assoc. 214: 1336–1341.


2. Watson, A. 2001. Indicators of renal insufficiency in dogs and cats presented at a veterinary teaching hospital. Aust. Vet. Practit. 31: 54–58.


bottom of page